Maintenance NeuroStar Transcranial Magnetic Stimulation (TMS) in Patients With Major Depressive Disorder

NCT ID: NCT01415154

Last Updated: 2025-03-04

Basic Information

• Recruitment Status: COMPLETED
• Clinical Phase: NA
• Total Enrollment: 67 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2011-08-31
• Study Completion Date: 2014-07-31

Brief Summary

The purpose of this study is to evaluate the efficacy of scheduled maintenance Transcranial Magnetic Stimulation (TMS) treatment compared to on-demand TMS treatment for symptomatic worsening in patients who have shown a clinical response to acute TMS treatment.

Detailed Description

This is a 12-month maintenance treatment study for patients who have responded to a 6 week course of acute TMS treatment for major depressive disorder (MDD). The study will seek to assess the change in depressive symptomatology across the duration of maintenance treatment using observer and self-administered efficacy measures. Describe the efficacy of TMS re-introduction in patients not receiving maintenance pharmacotherapy who show a recurrence of depressive symptoms. Assess the safety and durability of acute TMS therapy followed by maintenance TMS treatment for up to 12 months.

Conditions

Major Depressive Disorder

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: PARALLEL
• Primary Study Purpose: TREATMENT
• Blinding Strategy: NONE

Study Groups

Scheduled Treatment Arm

Following completion of the efficacy assessments at Week 6, One NeuroStar TMS session every four week and TMS reintroduction as needed for clinical deterioration.

Group Type: ACTIVE_COMPARATOR

NeuroStar TMS

Intervention Type: DEVICE

NeuroStar TMS treatmant - 120% of Observed MT, 10 pulses per second, 4 second on-time, 26 second off-time, 75 trains, 3,000 total pulses/sessions for 6 days. 3 treatments in taper week 1, 2 treatments in taper week 2 and 1 treatment in taper week 3.

Monthly Observational Follow up Arm

Following completion of the efficacy assessments at Week 6, Office follow up every 4 week and NeuroStar TMS reintroduction as needed for clinical deterioration.

Group Type: NO_INTERVENTION

No interventions assigned to this group

Interventions

NeuroStar TMS

NeuroStar TMS treatmant - 120% of Observed MT, 10 pulses per second, 4 second on-time, 26 second off-time, 75 trains, 3,000 total pulses/sessions for 6 days. 3 treatments in taper week 1, 2 treatments in taper week 2 and 1 treatment in taper week 3.

Intervention Type: DEVICE

Eligibility Criteria

Inclusion Criteria

• Primary diagnosis by DSM-IV criteria for Major Depressive Episode, single episode or recurrent course of illness, with the additional stipulation of a duration for this episode of ≥ 4 weeks and CGI-S ≥ 4.
• Duration of current episode of depression ≤ 3 years (the definition of an episode is demarcated by a period of ≥ 2 months when the patient did not meet full criteria for the DSM-IV definition of Major Depressive Episode.
• Capable and willing to provide informed consent.
• Signed HIPAA authorization.
• Able to adhere with the treatment schedule, and withdrawal of ongoing pharmacotherapy.
• If currently taking antidepressant pharmacotherapy, must be clinically appropriate to discontinue treatment with those agents.

Exclusion Criteria

• Investigators, site personnel directly affiliated with this study, and their immediate families (immediate family is defined as a spouse, parent, child or sibling, whether by birth or legal adoption).
• Individuals diagnosed by the Investigator with the following conditions (current unless otherwise stated):

• Depression secondary to a general medical condition, or substance- induced;
• Seasonal pattern of depression as defined by DSM-IV;
• History of substance abuse or dependence within the past year except nicotine and caffeine);
• Any psychotic disorder (lifetime), including schizoaffective disorder, or major depression with psychotic features in this or previous episodes;
• Bipolar disorder;
• Eating disorder (current or within the past year);
• Obsessive compulsive disorder (lifetime); or
• Post-traumatic stress disorder (current or within the past year).
• An Axis II Personality Disorder, which in the judgment of the Investigator may hinder the patient in completing the procedures required by the study protocol.
• Individuals with a clinically defined neurological disorder or insult including, but not limited to:

• Any condition likely to be associated with increased intracranial pressure;
• Space occupying brain lesion;
• History of cerebrovascular accident;
• Transient ischemic attack within two years;
• Cerebral aneurysm;
• Dementia;
• Parkinson's disease;
• Huntington's chorea;
• Multiple sclerosis.
• Increased risk of seizure for any reason, including but not limited to prior diagnosis of increased intracranial pressure (such as after large infarctions or trauma), or history of significant head trauma with loss of consciousness for ≥ 5 minutes.
• History of treatment with Vagus Nerve Stimulation.
• Cardiac pacemakers, implanted medication pumps, intracardiac lines, or acute, unstable cardiac disease.

• Minimum Eligible Age: 18 Years
• Maximum Eligible Age: 70 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Neuronetics

OTHER

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

David G. Brock, MD

Role: STUDY_DIRECTOR

Neuronetics

Locations

Rush University Medical Center

Chicago, Illinois, United States

Sheppard Pratt Health System

Baltimore, Maryland, United States

Premier Psychiatric Group, L.L.C.

Lincoln, Nebraska, United States

Butler Hospital

Providence, Rhode Island, United States

Medical University of South Carolina

Charleston, South Carolina, United States

Center for Anxiety and Depression

Mercer Island, Washington, United States

Countries

United States

Other Identifiers

44-03001-000

Identifier Type: -

Identifier Source: org_study_id